These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 28859290)

  • 1. Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study.
    Troester MA; Sun X; Allott EH; Geradts J; Cohen SM; Tse CK; Kirk EL; Thorne LB; Mathews M; Li Y; Hu Z; Robinson WR; Hoadley KA; Olopade OI; Reeder-Hayes KE; Earp HS; Olshan AF; Carey LA; Perou CM
    J Natl Cancer Inst; 2018 Feb; 110(2):176-82. PubMed ID: 28859290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features.
    Benefield HC; Reeder-Hayes KE; Nichols HB; Calhoun BC; Love MI; Kirk EL; Geradts J; Hoadley KA; Cole SR; Earp HS; Olshan AF; Carey LA; Perou CM; Troester MA
    JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33442657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
    Carey LA; Perou CM; Livasy CA; Dressler LG; Cowan D; Conway K; Karaca G; Troester MA; Tse CK; Edmiston S; Deming SL; Geradts J; Cheang MC; Nielsen TO; Moorman PG; Earp HS; Millikan RC
    JAMA; 2006 Jun; 295(21):2492-502. PubMed ID: 16757721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover.
    Clarke CA; Keegan TH; Yang J; Press DJ; Kurian AW; Patel AH; Lacey JV
    J Natl Cancer Inst; 2012 Jul; 104(14):1094-101. PubMed ID: 22773826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of molecular subtype and race on HR+, HER2- breast cancer survival.
    Reid S; Haddad D; Tezak A; Weidner A; Wang X; Mautz B; Moore J; Cadiz S; Zhu Y; Zheng W; Mayer IA; Shu XO; Pal T
    Breast Cancer Res Treat; 2021 Oct; 189(3):845-852. PubMed ID: 34331630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status.
    Ma H; Lu Y; Malone KE; Marchbanks PA; Deapen DM; Spirtas R; Burkman RT; Strom BL; McDonald JA; Folger SG; Simon MS; Sullivan-Halley J; Press MF; Bernstein L
    BMC Cancer; 2013 May; 13():225. PubMed ID: 23642215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups.
    Kurian AW; Fish K; Shema SJ; Clarke CA
    Breast Cancer Res; 2010; 12(6):R99. PubMed ID: 21092082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of breast cancer subtypes among African American women in the AMBER consortium.
    Allott EH; Geradts J; Cohen SM; Khoury T; Zirpoli GR; Bshara W; Davis W; Omilian A; Nair P; Ondracek RP; Cheng TD; Miller CR; Hwang H; Thorne LB; O'Connor S; Bethea TN; Bell ME; Hu Z; Li Y; Kirk EL; Sun X; Ruiz-Narvaez EA; Perou CM; Palmer JR; Olshan AF; Ambrosone CB; Troester MA
    Breast Cancer Res; 2018 Feb; 20(1):12. PubMed ID: 29409530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.
    Lund MJ; Trivers KF; Porter PL; Coates RJ; Leyland-Jones B; Brawley OW; Flagg EW; O'Regan RM; Gabram SG; Eley JW
    Breast Cancer Res Treat; 2009 Jan; 113(2):357-70. PubMed ID: 18324472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic features of breast cancer differ between women in the Democratic Republic of Congo and Belgium.
    Luyeye Mvila G; Batalansi D; Praet M; Marchal G; Laenen A; Christiaens MR; Brouckaert O; Ali-Risasi C; Neven P; Van Ongeval C
    Breast; 2015 Oct; 24(5):642-8. PubMed ID: 26279132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State.
    Kohler BA; Sherman RL; Howlader N; Jemal A; Ryerson AB; Henry KA; Boscoe FP; Cronin KA; Lake A; Noone AM; Henley SJ; Eheman CR; Anderson RN; Penberthy L
    J Natl Cancer Inst; 2015 Jun; 107(6):djv048. PubMed ID: 25825511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas.
    Huo D; Hu H; Rhie SK; Gamazon ER; Cherniack AD; Liu J; Yoshimatsu TF; Pitt JJ; Hoadley KA; Troester M; Ru Y; Lichtenberg T; Sturtz LA; Shelley CS; Benz CC; Mills GB; Laird PW; Shriver CD; Perou CM; Olopade OI
    JAMA Oncol; 2017 Dec; 3(12):1654-1662. PubMed ID: 28472234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study.
    O'Brien KM; Cole SR; Tse CK; Perou CM; Carey LA; Foulkes WD; Dressler LG; Geradts J; Millikan RC
    Clin Cancer Res; 2010 Dec; 16(24):6100-10. PubMed ID: 21169259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer.
    Ren X; Song Y; Zhang Y; Wu H; Chen L; Pang J; Zhou L; Shen S; Liang Z
    BMC Cancer; 2022 May; 22(1):548. PubMed ID: 35568835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.
    Ihemelandu CU; Leffall LD; Dewitty RL; Naab TJ; Mezghebe HM; Makambi KH; Adams-Campbell L; Frederick WA
    J Surg Res; 2007 Nov; 143(1):109-18. PubMed ID: 17950079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial comparison of receptor-defined breast cancer in Southern African women: subtype prevalence and age-incidence analysis of nationwide cancer registry data.
    Dickens C; Duarte R; Zietsman A; Cubasch H; Kellett P; Schüz J; Kielkowski D; McCormack V
    Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2311-21. PubMed ID: 25143359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 status and disparities in luminal breast cancers.
    Holowatyj AN; Ruterbusch JJ; Ratnam M; Gorski DH; Cote ML
    Cancer Med; 2016 Aug; 5(8):2109-16. PubMed ID: 27250116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Borderline Estrogen Receptor-Positive Breast Cancers in Black and White Women.
    Benefield HC; Allott EH; Reeder-Hayes KE; Perou CM; Carey LA; Geradts J; Sun X; Calhoun BC; Troester MA
    J Natl Cancer Inst; 2020 Jul; 112(7):728-736. PubMed ID: 31742342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.